Skip to content

Methode Electronics MEI Medical — Intangible Amortization

Other segment segments

Industrial
$3.8M+5.6%
Automotive
$1.9M-13.6%
Corporate And Intersegment Elimination
$0
Interface
$0

Similar metrics at other companies

Novanta logo
NOVTMedical Solutions — Intangible Amortization
$3.66M+16.2%
Leidos Holdings logo
LDOSHealth — Intangible Amortization
$4M-33.3%
Opko Health logo
OPKPharmaceutical — Intangible Amortization
$16.43M+2.0%
Catalyst Pharmaceutical logo
CPRXAmortization Expenses Of Intangible Asset
$9.7M+3.8%
Hayward Holdings logo
HAYWIntangible Amortization
$6.37M-6.9%
Johnson & Johnson logo
JNJInnovative Medicine — Amortization
$800M+33.3%

Other financials

Income statement

See full
Revenue$298.1M+15.9%
Gross profit$72.2M+268%
Operating income$10.9M+146%
Net income-+100%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$139.6M+34.7%
Total debt$348.6M+1.4%
Total equity$677.5M-2.3%
Total assets$1.3B0.0%

Cash flow

See full
Operating cash flow$4.9M-86.2%
CapEx$5.8M-36.3%
Free cash flow$10.1M

Valuation

See full
Market cap$638.49M+99.2%
Enterprise value$847.49M+51.2%
P/S0.6×+0.3×

Profitability

See full
Gross margin19.8%+4.2pp
Operating margin0.9%+0.5pp
Net margin-3.5%-1.0pp
FCF margin4.3%-0.4pp

Returns & leverage

See full
Return on equity-5.3%-1.5pp
Debt / equity0.5×0.0×
Current ratio2.4×0.0×

Where this comes from

Reported directly by Methode Electronics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Methode Electronics’s 10-K, filed June 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Methode Electronics's medical — intangible amortization.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Methode Electronics's medical — intangible amortization?
Methode Electronics (MEI) reported medical — intangible amortization of $0 in Q1 2026.
What does medical — intangible amortization mean?
Represents the systematic allocation of the cost of intangible assets, such as patents or acquired technology, over their useful lives within the medical segment. It reflects the non-cash expense of utilizing acquired intellectual property.